Skip to main content
Caplight Logo









Sermonix Pharmaceuticals

Sermonix Pharmaceuticals

Private
Columbus, OhioHealthcare & Life Scienceshttps://sermonixpharma.com/

Last Round

Strategic

Dec 18, 2023

Total Funding Raised

$107.1M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Sermonix Pharmaceuticals is a biotechnology company that develops and commercializes female-specific oncology products, with a focus on treating ESR1-mutated metastatic breast and gynecological cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticallasofoxifeneselective estrogen receptor modulatorSERMbreast cancer therapeuticsoncologyESR1 mutationclinical trialprecision medicinedrug developmentmetastatic breast cancerendocrine therapybiotech startuppharma licensingwomen's health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sermonix Pharmaceuticals Comparables

Compare Sermonix Pharmaceuticals with similar companies based on industry and business-model similarity.

Sermonix Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Olema Oncology
80%
Arvinas Inc
80%
Kind Pharmaceutical
80%

Sermonix Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicDec 18, 2023
Series A ExtensionNov 15, 2021
Series AJul 31, 2019
SeedOct 31, 2017
SeedNov 10, 2016

Sermonix Pharmaceuticals Investors

Notable investors and investment history

Sermonix Pharmaceuticals investors
InvestorRounds
Perceptive AdvisorsSeries A Extension
XontogenySeries A Extension
WILD Family OfficeSeries A
HP WILD HOLDING AGSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 18, 2025

    Global rights for certain assets acquired by Athira Pharma.

  • Mar 25, 2025

    Partnering with Regor Pharmaceuticals to advance breast cancer treatment.

Sermonix Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sermonix Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sermonix Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersColumbus, Ohio
Employee Range8
Year Founded2014
Last FundingDec 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?